Krazati (adagrasib) Patient Assistance Program
Don’t let the high cost of brand KRAS G12C inhibitor disrupt your KRAS G12C-mutated cancer treatment. We help eligible patients access Krazati (adagrasib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Krazati (adagrasib) is FDA-approved for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (after prior systemic therapy) and KRAS G12C-mutated locally advanced or metastatic colorectal cancer (with cetuximab, after prior fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy). Selective oral KRAS G12C inhibitor — covalently binds and traps the inactive GDP-bound conformation of KRAS G12C.
- Without assistance, Krazati costs commonly run approximately $20,000–$25,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Krazati for a flat $69.95 per month.
- Other KRAS G12C inhibitors: sotorasib (Lumakras — first-in-class, also FDA-approved for NSCLC and CRC with cetuximab in CodeBreaK 300). Both available for the same indications generally. KRAS G12C mutations occur in approximately 13% of NSCLC and 3–4% of CRC. Standard care if KRAS G12C-negative or if not eligible: chemotherapy + checkpoint inhibitor (Keytruda, Tecentriq, Opdivo) for NSCLC; chemotherapy ± EGFR inhibitor (Erbitux, Vectibix) for CRC; PD-1 + chemotherapy for some. Tumor molecular testing essential for KRAS G12C identification.
What is Krazati Prescription Assistance Program?
The Krazati Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Krazati (used for KRAS G12C-mutated NSCLC and CRC) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, KRAS G12C mutation documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Krazati PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including tumor KRAS G12C testing results, prior treatment history, and indication-specific criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Krazati KRAS G12C inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Krazati enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cancer treatment.
Pharmacy Price Comparison
- Without assistance, Krazati costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted cancer therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Krazati advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic platinum doublet | ~$500/cycle | Generic chemo backbone alt |
| Walgreens | ~$24,000/mo | Save substantially |
| CVS Pharmacy | ~$25,000/mo | Save substantially |
| Walmart | ~$21,000/mo | Save substantially |
| Specialty pharmacy | ~$20,000/mo | Save substantially |
| Lumakras (alt KRAS G12C) | ~$20,000/mo | Alt KRAS G12C inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Krazati — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Krazati Prescription Program?
The Krazati Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. KRAS G12C testing is essential for Krazati candidacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Krazati assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Krazati is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Krazati:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $20,000–$25,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Krazati assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Krazati Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Krazati:
Krazati is a covalent KRAS G12C inhibitor — binds to the cysteine at position 12 of mutant KRAS G12C protein, trapping it in the inactive GDP-bound conformation and preventing downstream RAS/RAF/MEK/ERK proliferative signaling. KRAS was long considered ‘undruggable’ until covalent G12C-specific inhibitors emerged. KRYSTAL-1 and KRYSTAL-12 trials established Krazati’s role in pretreated NSCLC and CRC.
How It Works:
KRAS is a small GTPase that switches between active GTP-bound and inactive GDP-bound states. KRAS G12C mutation (glycine to cysteine at position 12) creates a constitutively active oncogenic driver in ~13% of NSCLC and ~3–4% of CRC. Activated KRAS drives downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling for proliferation and survival. Adagrasib covalently binds the mutant cysteine at position 12 — selectively locks KRAS G12C in its inactive GDP-bound conformation, blocks downstream signaling, and produces tumor regression in KRAS G12C-mutated cancers. Krazati has good CNS penetration (relevant for brain metastases in NSCLC). Combination with cetuximab (anti-EGFR) is required in CRC due to EGFR-mediated feedback adaptive resistance in this tumor type.
Form and Use:
Krazati 200 mg tablets. Recommended dose 600 mg twice daily (3 tablets BID). Take with or without food. Continue until disease progression or unacceptable toxicity. Dose adjustments for QT prolongation, hepatic toxicity, ILD/pneumonitis. Periodic ECG (QT monitoring), CBC, comprehensive metabolic panel. Avoid strong CYP3A4 inhibitors (may dose-reduce) and inducers (avoid).
Generic Availability:
No generic Krazati. Other KRAS G12C inhibitor: sotorasib (Lumakras — first-in-class, FDA-approved for NSCLC after prior therapy and for CRC with cetuximab per CodeBreaK 300). Both inhibitors are appropriate for the same general indications. Choice often by clinical trial data interpretation, insurance, and clinician preference. For KRAS G12C-negative or non-eligible patients: chemotherapy + checkpoint inhibitor (Keytruda, Tecentriq, Opdivo, Imfinzi) in NSCLC; chemotherapy ± EGFR antibody (cetuximab/Erbitux, panitumumab/Vectibix) in CRC; antiangiogenic options (bevacizumab biosimilars, ramucirumab/Cyramza, regorafenib generic). NCCN guidelines and tumor genetic testing guide selection. For other oncogenic drivers: EGFR TKIs (Tagrisso, Tarceva, etc.), ALK TKIs (Alecensa, Alunbrig, Lorbrena), ROS1 (Rozlytrek, Xalkori), BRAF V600E, MET exon 14, RET, HER2, NTRK targeted therapies as appropriate.
Warnings:
Hepatotoxicity (severe ALT/AST elevations — monitor LFTs at baseline and frequently first 3 months), QTc prolongation (avoid additional QT-prolonging drugs; monitor ECG and electrolytes), interstitial lung disease and pneumonitis (sometimes severe), gastrointestinal adverse reactions (diarrhea, nausea, vomiting — common and sometimes severe), embryo-fetal toxicity. Other: fatigue, decreased appetite, peripheral edema, cytopenias, electrolyte disturbances. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase adagrasib — caution; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid. PPIs and H2 blockers may reduce adagrasib absorption — manage timing.
FAQ (Frequently Asked Questions)
How much does Krazati cost without insurance?
$20,000–$25,000 per month. Annual cost exceeds $250,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients.
Is Krazati considered chemotherapy?
No — Krazati is a targeted oral therapy (selective KRAS G12C inhibitor) — not traditional cytotoxic chemotherapy. Different toxicity profile and selective for KRAS G12C-mutated tumors.
Why is KRAS G12C testing required before starting Krazati?
Krazati selectively targets the KRAS G12C mutation — tumors without this specific mutation will not respond. Tumor or liquid biopsy molecular testing (next-generation sequencing or PCR-based panels) identifies KRAS G12C mutations. Approximately 13% of NSCLC and 3–4% of CRC harbor KRAS G12C.
What is the difference between Krazati and Lumakras (sotorasib)?
Both are KRAS G12C covalent inhibitors with FDA approval for KRAS G12C-mutated NSCLC and CRC (with cetuximab). Krazati (adagrasib) has slightly better CNS penetration (relevant for brain metastases) and twice-daily dosing. Lumakras (sotorasib) is once-daily. Both effective; choice often by clinician preference, prior trials, and insurance.
Why is cetuximab required with Krazati for colorectal cancer?
In CRC, EGFR-mediated feedback adaptive resistance limits KRAS G12C inhibitor monotherapy efficacy. Combining cetuximab (anti-EGFR antibody) with Krazati blocks this resistance pathway and produces meaningful response rates. The KRYSTAL-1 CRC cohort and CodeBreaK 300 trial (with sotorasib) established this combination strategy.
Take Control of Your Medication Costs
Targeted therapy for KRAS G12C-mutated cancers should not be derailed by cost. Genetic testing and proper patient selection are essential. Our Krazati advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Krazati through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.